To assess SCLC heterogeneity in the RP model, we use both NE marker NCAM and mesenchymal marker CD44 to do the immunostaining and FACS analyses, and identify the NCAMhiCD44lo/– cells as the SCLC metastasizing cells. This evidence concerns the gene NCAM1 and small cell lung carcinoma.